G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 16:20 ET | G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1_Logo_2022_Reg.png
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024 06:30 ET | G1 Therapeutics
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1_Logo_2022_Reg.png
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:30 ET | G1 Therapeutics
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1_Logo_2022_Reg.png
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
February 15, 2024 08:30 ET | G1 Therapeutics
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
G1_Logo_2022_Reg.png
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024 16:05 ET | G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1_Logo_2022_Reg.png
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 06:45 ET | G1 Therapeutics
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
G1_Logo_2022_Reg.png
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 09:00 ET | G1 Therapeutics
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 16:51 ET | G1 Therapeutics
January 2024 Inducement Grants
G1_Logo_2022_Reg.png
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023 09:26 ET | G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023 16:27 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...